Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Evaluation of the Efficacy of a Probiotic Product as an Adjuvant Treatment for Vulvovaginal Candidiasis

18 mei 2026 bijgewerkt door: Bioithas SL

Open-label, randomized clinical trial with a control group and a 4-week intervention period. The study will evaluate the efficacy of the probiotic supplement Bioithas WOMAN® as an adjunctive treatment in women with clinically suspected vulvovaginal candidiasis (VVC).

All participants will receive the antifungal treatment prescribed by the investigator. Participants allocated to the probiotic group will additionally receive Bioithas WOMAN®, supplied as a bottle containing 30 capsules, to be taken during the 4-week intervention period.

The study includes two on-site visits: Visit 1 (baseline) and Visit 2 (week 4/end of study). At baseline, demographic data, relevant gynecological history, VVC risk factors, clinical characteristics of the current episode, concomitant diseases, and usual pharmacological treatments will be recorded. Clinical symptoms associated with VVC, including abnormal vaginal discharge, pruritus, burning sensation, irritation, and dyspareunia, will be assessed, together with the Vaginitis Symptom Score (VSS).

At both visits, vaginal pH will be measured using an indicator strip applied to the vaginal mucosa. A vaginal sample will also be collected using a sterile swab for microbiological culture of Candida and semiquantitative assessment of Lactobacillus. Although randomization will be performed in women with clinical suspicion of VVC, microbiological confirmation by culture will be obtained after inclusion.

At the final visit, the same clinical and microbiological variables will be reassessed. Concomitant treatments, relevant follow-up observations, and any adverse events reported during the study will also be recorded. In the probiotic group, adherence to treatment will be assessed by counting the remaining capsules.

Studie Overzicht

Toestand

Werving

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

Open-label, randomized clinical trial with a control group and a 4-week intervention period.

During the study, 2 on-site visits will be carried out:

Visit 1 (V1) - Study start: Inclusion of cases and controls Visit 2 (V2) - End of study: Week 4 of treatment and follow-up

The procedures performed at each visit are described below:

Visit 1 (V1) - Study start

Participation in the study will be proposed to patients attending the Gynecology outpatient clinics of Torrevieja University Hospital with a clinical suspicion, in the investigator's judgment, of vulvovaginal candidiasis (VVC). The investigator will provide them with the patient information sheet so that potential participants can understand the study procedures and objectives after carefully reading it, as well as ask any questions that may arise.

If the participant expresses interest in taking part in the study, she will be given two copies of the informed consent form to complete and sign, so that her willingness to participate in the study is duly documented.

After this, all inclusion and exclusion criteria will be checked one by one, so that the volunteer may ultimately participate in the study if all inclusion criteria and none of the exclusion criteria are met. At that point, she will be assigned a clinical trial participant number in order of inclusion, by which she will be identified.

The following data will be collected in the Case Report Form (CRF):

  • Demographic data: age, BMI, concomitant diseases, and usual pharmacological treatments.
  • Clinical characteristics of the VVC episode: predominant symptoms, severity of the clinical condition, and prescribed antifungal treatment.
  • Relevant gynecological history and VVC risk factors.

The clinical variables under study will be collected:

- Presence or absence (yes/no) of the usual symptoms associated with VVC: Abnormal vaginal discharge Pruritus Burning sensation Irritation Dyspareunia

  • Vaginitis Symptom Score (VSS)
  • In addition, vaginal pH will be measured using a pH indicator strip applied to the vaginal mucosa.
  • A vaginal sample will also be collected for microbiological culture of Candida and culture for semiquantitative assessment of Lactobacillus.

The vaginal sample will be collected using a sterile swab. The swab will be rubbed and rotated over the vaginal mucosa to obtain secretion. The collected sample will be placed in the transport medium indicated by the center's laboratory, appropriately labeled, and sent for microbiological culture of Candida and Lactobacillus following the laboratory's standard procedures.

According to the randomization list, participants will be assigned to either the treatment group or the control group. Randomization will be performed in patients with clinical suspicion of VVC, although microbiological confirmation by culture will be carried out after inclusion.

Participants assigned to the treatment group will be provided with a bottle containing 30 capsules of the probiotic supplement Bioithas WOMAN®, which they will add to the antifungal treatment prescribed at the visit, whereas participants in the control group will receive only the antifungal treatment.

Visit 2 (V2) - End of study

As in Visit 1, the clinical variables under study will be collected:

  • Presence or absence of the usual symptoms associated with vaginitis
  • Vaginitis Symptom Score (VSS)

In addition, the following will be performed:

  • Vaginal pH measurement
  • Vaginal sample for microbiological culture of Candida and culture for semiquantitative assessment of Lactobacillus

Additionally, concomitant treatments and relevant observations during the follow-up period will be recorded, as well as any reported adverse events.

For participants in the probiotic group, treatment adherence will be assessed by counting the remaining capsules.

Studietype

Ingrijpend

Inschrijving (Geschat)

60

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studiecontact

Studie Contact Back-up

Studie Locaties

  • Spanje
    • Alicante
      • Torrevieja, Alicante, Spanje, 03186
        • Werving
        • Hospital Universitario de Torrevieja
        • Contact:
        • Contact:
        • Hoofdonderzoeker:
          • Eduardo Cazorla Amorós, MD
        • Onderonderzoeker:
          • Duska Beric, MD
        • Onderonderzoeker:
          • Elisa Peñalver Escolano, MD
        • Onderonderzoeker:
          • Ana María Navarro Fenoll, SN

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

  • Kind
  • Volwassen
  • Oudere volwassene

Accepteert gezonde vrijwilligers

Nee

Beschrijving

Inclusion Criteria:

  • Women of reproductive age who use effective contraceptive methods during the course of the study.
  • Clinical suspicion of vulvovaginal candidiasis, in the investigator's judgment, based on the presence of symptoms - e.g., pruritus, burning sensation, irritation, dyspareunia and/or abnormal vaginal discharge - and/or compatible clinical findings.
  • Possibility of collecting a vaginal sample at the baseline visit for microbiological analysis.
  • Ability and willingness to comply with the study procedures and to sign the informed consent form

Exclusion Criteria:

  • Menstruation at the time of inclusion.
  • Pregnancy or breastfeeding.
  • Menopause or perimenopause.
  • Diabetes mellitus.
  • Presence of immunocompromised status or treatment with immunosuppressants within the 3 months prior to inclusion in the trial.
  • Vaginal coinfection in addition to vulvovaginal candidiasis.
  • Severe chronic diseases or other active infections that may interfere with the clinical assessment of vulvovaginal candidiasis, in the investigator's judgment.
  • History of intolerance or hypersensitivity to the intervention products.
  • Treatment with antifungals or probiotic supplements in the month prior to inclusion in the trial.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: Gerandomiseerd
  • Interventioneel model: Parallelle opdracht
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Geen tussenkomst: Controlegroep
Experimenteel: Bioithas WOMAN®
Voedingssupplement: Bioithas WOMAN®
≥1 × 10⁹ CFU of a probiotic blend composed of Lacticaseibacillus rhamnosus, Lactiplantibacillus plantarum, and Kluyveromyces marxianus

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Difference in the number and percentage of patients with complete absence of symptoms associated with VVC at the end of the 4-week treatment period between the study groups, compared with the baseline visit.
Tijdsspanne: 4 weeks
The complete absence of symptoms associated with VVC will be assessed. The symptoms evaluated will include: abnormal vaginal discharge, pruritus, burning sensation, irritation, and dyspareunia
4 weeks

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Difference in the number and percentage of patients with absence of each individual symptom associated with VVC at the end of the 4-week treatment period between the study groups, compared with the baseline visit.
Tijdsspanne: 4 weeks
The absence of each symptom associated with VVC will be assessed separately. The symptoms evaluated will include: abnormal vaginal discharge, pruritus, burning sensation, irritation, and dyspareunia
4 weeks
Changes in the Vaginitis Symptom Score (VSS) at the end of the 4-week intervention period between the study groups, compared with the baseline visit
Tijdsspanne: 4 weeks

Vaginistis Symptom Score (VSS) is a clinical scale used to assess the presence and severity of symptoms associated with vulvovaginal candidiasis, based on the assessment of the main symptoms reported by the patient.

The VSS includes the evaluation of the following symptoms:

Abnormal vaginal discharge Vaginal pruritus Burning sensation Vaginal irritation Dyspareunia

Each symptom is scored individually according to its intensity, using an ordinal severity scale, usually defined as:

0 = Absent

  1. = Mild
  2. = Moderate
  3. = Severe

The total VSS score is obtained as the sum of the individual scores for each symptom, resulting in a total range from 0 to 15 points, where higher values indicate greater severity of vaginal symptoms.
4 weeks
Difference in the number and percentage of patients with a negative vaginal culture for Candida at the end of the 4-week treatment period between the study groups, compared with those with an initially positive culture at the baseline visit
Tijdsspanne: 4 weeks
Among patients in whom the diagnosis of vulvovaginal candidiasis is microbiologically confirmed by a positive Candida culture result, a follow-up culture will be performed at 4 weeks to assess culture negativization after the administered treatment
4 weeks
Adherence to the investigational product based on the count of capsules returned at the end of the treatment period among participants in the probiotic group
Tijdsspanne: 4 weeks
For participants in the probiotic group, the remaining treatment will be collected to assess adherence during the treatment period
4 weeks

Andere uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Number and severity of total adverse events reported by patients during the 4-week treatment period
Tijdsspanne: 4 weeks
All adverse events occurring during the study follow-up period will be collected
4 weeks
Number and severity of adverse events potentially attributable to the study product during the 4-week treatment period
Tijdsspanne: 4 weeks
Adverse events potentially attributable to the study product will be collected during the follow-up period, especially those of a digestive nature
4 weeks
Changes in vaginal pH at the end of the 4-week intervention period between the study groups, compared with the baseline visit
Tijdsspanne: 4 weeks
Vaginal pH will be measured using an indicator strip at the beginning and end of the study, with the aim of assessing possible changes after 4 weeks of follow-up
4 weeks
Changes in the vaginal load of Lactobacillus spp. at the end of the 4-week treatment period between the study groups, compared with the baseline visit.
Tijdsspanne: 4 weeks
Changes in the vaginal load of Lactobacillus spp. will be assessed by semiquantitative colony count (CFU) obtained through microbiological culture on selective medium
4 weeks

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Bioithas SL

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Geschat)

25 mei 2026

Primaire voltooiing (Geschat)

31 december 2026

Studie voltooiing (Geschat)

31 december 2026

Studieregistratiedata

Eerst ingediend

18 mei 2026

Eerst ingediend dat voldeed aan de QC-criteria

18 mei 2026

Eerst geplaatst (Werkelijk)

22 mei 2026

Updates van studierecords

Laatste update geplaatst (Werkelijk)

22 mei 2026

Laatste update ingediend die voldeed aan QC-criteria

18 mei 2026

Laatst geverifieerd

1 mei 2026

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • CVV.PROB

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Deidentified individual participant data underlying the results reported in the published article may be shared upon reasonable request, subject to approval by the sponsor and/or principal investigator, compliance with applicable data protection regulations, and execution of an appropriate data sharing agreement.

IPD-tijdsbestek voor delen

Beginning 6 months after publication and for 5 years thereafter

IPD-toegangscriteria voor delen

Access to the study data will be granted to qualified researchers upon justified request to the corresponding author

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren